Literature DB >> 16928240

Syndromes with genetic instability: model diseases for (skin) cancerogenesis.

Steffen Emmert1, Diana Leibeling, Thomas M Rünger.   

Abstract

Tumorigenesis is a multi-step process in which exogenous and endogenous mutational events lead to accumulation of DNA mutations resulting in loss of cellular growth control. During the last decades knowledge about the molecular mechanisms of DNA mutations and the cellular systems that counteract the degeneration of the genome has increased rapidly. This expansion was driven in part by clinical and molecular investigations of syndromes with genetic in-stability. These syndromes are typically associated with an increased predisposition for tumor formation. They include nucleotide excision repair defective syndromes, mismatch repair defective syndromes, and the chromosome break-age syndromes. These diseases mirror vividly the phenotypic consequences of the failure of important cellular systems for the maintenance of the genomic integrity. They significantly contribute to our understanding of the molecular mechanisms of (skin) carcinogenesis and for the development of preventive and therapeutic anticancer strategies.

Entities:  

Mesh:

Year:  2006        PMID: 16928240     DOI: 10.1111/j.1610-0387.2006.06047.x

Source DB:  PubMed          Journal:  J Dtsch Dermatol Ges        ISSN: 1610-0379            Impact factor:   5.584


  3 in total

1.  The role of XPD in cell apoptosis and viability and its relationship with p53 and cdk2 in hepatoma cells.

Authors:  Hong-yun Wang; Gao-fei Xiong; Ji-xiang Zhang; Hong Xu; Wu-hua Guo; Jiang-jing Xu; Xiang-yang Xiong
Journal:  Med Oncol       Date:  2011-01-25       Impact factor: 3.064

2.  [Xeroderma pigmentosum (XP) : A genetic disease sheds light on UV-induced skin cancer].

Authors:  B Emmert; E Hallier; M P Schön; S Emmert
Journal:  Hautarzt       Date:  2011-02       Impact factor: 0.751

Review 3.  Nucleotide excision repair and cancer.

Authors:  Diana Leibeling; Petra Laspe; Steffen Emmert
Journal:  J Mol Histol       Date:  2006-07-20       Impact factor: 3.156

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.